|
|
||||||||
Ann Thorac Surg 2004;78:1742-1747
© 2004 The Society of Thoracic Surgeons
a University of Milan, Milan, Italy
Accepted for publication April 27, 2004.
* Address reprint requests to Dr Raveglia, Piazza Leonardo da Vinci 7, 20133 Milan, Italy
ravegliafederico{at}tiscali.it
BACKGROUND: Pleomorphic carcinoma is a rare epithelial malignant tumor. Pulmonary pleomorphic carcinoma was introduced by the 1999 World Health Organization classification as a new peculiar type of lung carcinoma showing concurrent malignant epithelial and sarcomatoid spindle cell elements. Few reports describe its clinical behavior. My colleagues and I report a series of patients surgically treated for pulmonary pleomorphic carcinoma to describe our experience with this malignant neoplasm.
METHODS: Twenty cases of pleomorphic pulmonary carcinoma were collected and studied clinicopathologically. All patients underwent surgical resection. The cases were as follows: 6 stage I, 12 stage II, and 2 stage IIIA. Histologic diagnosis was established by using light microscopic examination and immunohistochemistry. Survival rates were calculated with the Kaplan-Meier method.
RESULTS: We postoperatively diagnosed 20 cases of pleomorphic carcinoma: 14 cases were exclusively spindle and giant-cell carcinomas, 2 cases were spindle and giant-cell carcinoma combined with adenocarcinoma, 2 were combined with squamous cell carcinoma, and 2 were combined with large cell carcinoma. At last follow-up, 4 patients were still alive; they were postoperative T1 N0 and T2 N0. The remaining 16 patients died from early distant metastases. The median duration of disease-free survival was 5 months. The median duration of overall survival was 8 months.
CONCLUSIONS: The prognosis of patients with pleomorphic carcinoma was poor, despite surgery and adjuvant chemotherapy, because of early relapse of disease. Nodal involvement was a determinant prognostic variable, because advanced stages were related to worse prognosis. In case of preoperatively proven pulmonary pleomorphic carcinoma, surgery should be recommended to N0 patients.
This article has been cited by other articles:
![]() |
Pulmonary puzzle Thorax, November 1, 2008; 63(11): 1005 - 1005. [Full Text] [PDF] |
||||
![]() |
S. Yamamoto, D. Hamatake, T. Ueno, T. Higuchi, M. Hiratsuka, T. Shiraishi, A. Iwasaki, and T. Shirakusa Clinicopathological investigation of pulmonary pleomorphic carcinoma Eur. J. Cardiothorac. Surg., December 1, 2007; 32(6): 873 - 876. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. W. Martin, A. M. Correa, N. G. Ordonez, J. A. Roth, S. G. Swisher, A. A. Vaporciyan, G. L. Walsh, and D. C. Rice Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis Ann. Thorac. Surg., September 1, 2007; 84(3): 973 - 980. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Venissac, D. Pop, S. Lassalle, F. Berthier, P. Hofman, and J. Mouroux Sarcomatoid lung cancer (spindle/giant cells): An aggressive disease? J. Thorac. Cardiovasc. Surg., September 1, 2007; 134(3): 619 - 623. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yuki, T. Sakuma, C. Ohbayashi, M. Yoshimura, N. Tsubota, Y. Okita, and M. Okada Pleomorphic carcinoma of the lung: A surgical outcome J. Thorac. Cardiovasc. Surg., August 1, 2007; 134(2): 399 - 404. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |